Johnson & Johnson ended its COVID-19 vaccine production agreements with Catalent Inc. and Sanofi SA, signaling that manufacturing levels are falling due to lower-than-expected demand, The Wall Street Journal reported on Friday.
United States Centers for Disease Control and Prevention data shows that health authorities in the country administered over 397 million Pfizer Inc.-BioNTech SE vaccines and over 249 million Moderna Inc. shots so far, compared to only just under 19 million Johnson & Johnson vaccines.
In addition, unnamed sources told the newspaper that Johnson & Johnson is engaged in arbitration against Merck & Co. Inc. over their US government-supported partnership announced back in March 2021.
